drugset
drugset / Trial / NCT00494026

Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)

NCT00494026 ↗

Phase 2 Terminated 4 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a multicenter, phase II, open-label trial to evaluate the efficacy of pemetrexed + carboplatin combined with thoracic radiotherapy in patients with Limited Stage of small cell lung cancer

Timeline

Start
2007-09
Primary completion
2008-10
Completion
2008-10

Outcome

Outcome not reported

Stopped: “Study stopped early based on interim results of another trial, showing inferior activity of pemetrexed/carboplatin compared to etoposide/carboplatin in SCLC.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

small cell lung carcinoma